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Objective- To assess outcomes of patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary 
intervention (PCI) in relation to smoking status and adjunctive antithrombotic therapy.
Methods- In HORIZONS-AMI trial, 3602 patients were randomly assigned to receive unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa 
inhibitor (GPI) or bivalirudin alone.
Results- Among 3328 patients with known smoking status following primary PCI, 1563 (47%) were current smokers. Outcomes stratified by 
smoking status and adjunctive antithrombotic therapy are shown in the table. In smokers, bivalirudin monotherapy compared with UFH + a GPI was 
associated with lower rates of combined adverse clinical events at 30 days and at 1 year due to lower rates of mortality and major bleeding. In non-
smokers, bivalirudin monotherapy was associated with lower rates of major bleeding at 30 days and 1 year and lower rates of reinfarction at 1 year. 
There was significant interaction between the antithrombotic assignment and smoking status in 30-day mortality (P=0.03).
Conclusions- In patients with STEMI treated with primary PCI, bivalirudin monotherapy, compared with UFH plus a GPI, reduced major bleeding 
regardless of smoking status. Reduction in mortality with bivalirudin monotherapy occurred in smokers but not in non-smokers with STEMI.
Outcomes, %
Smokers
N=1563 P 
Nonsmokers
N=1765 P Bivalirudin monotherapy
N=806
UFH + GPI
N=757
Bivalirudin monotherapy
N=864
UFH + GPI
N=901
30-day
Death 0.5 2.2 0.003 3.0 3.6 0.54
Reinfarction 2.4 2.0 0.61 1.8 1.7 0.90
Ischemic TVR 2.9 2.3 0.45 2.9 1.9 0.16
Stroke 0.5 0.5 0.93 0.6 0.6 0.94
Definite/probable stent thrombosis* 2.9 2.3 0.46 2.5 1.9 0.41
MACE§ 3.8 5.2 0.23 6.5 5.7 0.45
Major bleeding 3.7 8.9 <0.0001 6.5 9.6 0.01
Combined adverse clinical events† 6.6 12.3 0.0001 11.2 13.3 0.19
1-year
Death 1.8 4.0 0.008 4.4 5.5 0.32
Reinfarction 4.8 4.4 0.67 2.7 4.6 <0.05
Ischemic TVR 8.5 5.6 0.03 7.0 6.9 0.88
Stroke 1.0 1.4 0.53 0.8 0.7 0.72
Stent thrombosis 4.5 3.9 0.55 2.7 2.5 0.75
MACE§ 11.5 11.1 0.87 12.1 12.9 0.64
Major bleeding 4.5 9.0 0.0003 7.0 10.2 0.01
Combined adverse clinical events† 13.7 17.4 0.03 16.8 19.8 0.11
* By Academic Research Consortium (ARC) definition. § Death, reinfarction, ischemic TVR, or stroke. † MACE or major bleeding.
